Vitalis Migraine Prevention
Natural health product licensed in Canada
- Licence holder
- Wampole Group L.P.
- NPN or DIN-HM
- 80027022
- Status
- Active licence
- Licence date
- 22 August 2011
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Tanacetum parthenium Source : Feuille Potency : 0.8 % Parthenolide | 250 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
(Used in Herbal Medicine to) help(s) reduce the severity and/or frequency of migraine headaches and associated symptoms such as nausea and vomiting, when taken as a prophylactic.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are pregnant. Do not use if you are allergic to plants of the Asteraceae/Compositae/Daisy family.
Source
Official Health Canada record, licence 80027022
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Tanacetum parthenium
Read the warning, when it applies and the studies cited
FEVERFEW - TANACETUM PARTHENIUM
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.
Do not use if you are pregnant or breastfeeding (EMA 2020).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.